CDK4/6 Inhibitors-based Combinational Therapy for Human Cancers
Cyclin-dependent kinases (CDKs) inhibitors have been approved in the combination with hormone-based therapy for advanced breast cancer. In addition to endocrine therapy, the combinations of CDK4/6 inhibitors with epidermal growth factor receptor (EGFR) inhibitors, phosphoinositide 3-kinase (PI3K)/ma...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Magazine House of Cancer Research on Prevention and Treatment
2019-01-01
|
| Series: | Zhongliu Fangzhi Yanjiu |
| Subjects: | |
| Online Access: | http://html.rhhz.net/ZLFZYJ/html/8578.2019.18.0906.htm |
| Summary: | Cyclin-dependent kinases (CDKs) inhibitors have been approved in the combination with hormone-based therapy for advanced breast cancer. In addition to endocrine therapy, the combinations of CDK4/6 inhibitors with epidermal growth factor receptor (EGFR) inhibitors, phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitors, chemotherapy, immune therapy, molecular targeted agents and the other therapeutics could overcome its resistance and improve clinical benefits. CDK4/6 inhibitors-based combinational therapeutics provides a promising window for human cancer treatment. |
|---|---|
| ISSN: | 1000-8578 1000-8578 |